New Alzheimer's drug trial uses eye scans to track brain changes
NCT ID NCT07604896
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called lecanemab in 200 people with early-stage Alzheimer's. Participants receive either lecanemab or standard care for 24 months. Researchers use eye and brain scans along with memory tests to see if the drug slows the disease and to check for side effects like brain swelling.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DEMENTIA (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your brain help unlock Alzheimer's secrets?
- Can a gene therapy clear the toxic tau tangle in Alzheimer's?
- Can a new drug tame Alzheimer's? early trial aims to find out
- A scan that sees Alzheimer's tangles? trial puts tau tracer to the test
- Can a pill clear the toxic proteins behind Alzheimer's?
- A light switch for better sleep? Alzheimer's trial tests wireless circadian lighting